PA-PMI
12.9.2019 15:02:08 CEST | Business Wire | Press release
Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI @ Work: New Projects, New Thinking. The report, a companion piece to AI Innovators: Cracking the Code on Project Performance , explores how artificial intelligence (AI) is changing the way projects are managed and delivered globally.
As AI projects become the norm, project managers need to better understand what technologies will help them streamline and improve their AI-based project work -- or they risk being left behind. The new report highlights the top AI technologies project leaders are currently leveraging to boost project management productivity, and how to incorporate AI technologies into their overall project work.
While project leaders are tapping into AI technologies to boost project productivity and quality, unlocking AI’s full potential requires building and constantly refreshing knowledge of emerging technologies. In fact, the report finds that organizations and their project leaders will need a high Project Management Technology Quotient (PMTQ) – a way of evaluating an organization’s ability to manage and integrate technology based on the needs of the organization or the project at hand – to turn AI strategy into reality.
“In today’s increasingly project-based economy, the most forward-thinking organizations know that the success of their strategies hinges on how well they can execute projects. And the race toward AI mastery is no exception,” said Michael DePrisco, vice president of global solutions at PMI. “As we see AI technologies continue to be integrated into organizations, the research indicates that project managers, especially those with a high PMTQ, are well prepared to play an integral role in implementation.”
Of the respondents to the study, 50 percent reported a high PMTQ (Innovators) and 10 percent reported only sometimes or never practicing the principles of the PMTQ (Laggards).
A majority of both groups say their project management skills and experience are a good foundation for managing AI. But the Innovators have the upper hand: 74 percent of Innovators say they’re confident their current skill set enables them to work with AI, compared with 51 percent of Laggards.
Even more so, Innovators cite having more awareness and experience with several AI technologies, including knowledge-based systems, decision management, speech recognition, and expert systems. These respondents also report delivering better outcomes when using AI technologies, including a decreased amount of time spent on activities like monitoring progress, managing documentation, as well as activity and resource planning.
The top technologies respondents cite as enhancing productivity are:
- Robotic process automation: Technology that mimics and automates human tasks to support corporate processes.
- Machine learning: Technology that allows computers to learn by employing pattern detection for improved decisions in subsequent situations.
- Reinforcement learning: A machine learning technique that enables software to learn in an interactive environment by trial and error using feedback from its own actions.
The top technologies respondents identify as increasing quality are:
- Anti-bias solutions: Technology that automatically identifies bias in a range of AI algorithms.
- Expert systems: Technology that emulates and mimics human intelligence, skills or behavior and usually offers expert knowledge in a particular field, topic, or skill.
- Knowledge-based systems: Technology that understands the context of the data being processed to help problem-solve procedures and support human learning, decision making, and actions.
While it is clear AI can make a difference in value delivery, it is up to organizations and their project leaders to identify and understand which technologies can best help them achieve their specific goals and deliver long-term success.
Read more about 2019 Pulse of the Profession® In-Depth Report: AI Innovators: AI @ Work: New Projects, New Thinking. The Pulse of the Profession® In-Depth research was conducted online in June/July 2019 among 780 project management practitioners globally.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Founded in 1969, PMI delivers value for more than three million professionals working in nearly every country in the world through global advocacy, collaboration, education and research. We advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
